Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Aurinia Pharmaceuticals ( (AUPH) ) has issued an announcement.
Aurinia Pharmaceuticals announced it will release its financial and operational results for the fourth quarter and full year of 2024 on February 27, 2025. The announcement will be accompanied by a conference call and webcast hosted by the management team, providing insight into the company’s performance and future business plans. This release may have implications for stakeholders by highlighting the company’s financial health and strategic direction.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company that specializes in developing therapies for autoimmune diseases, particularly where there is a high unmet medical need. The company is known for its product LUPKYNIS®, the first FDA-approved oral therapy for active lupus nephritis. Aurinia is also working on developing AUR200, a dual inhibitor aimed at treating autoimmune diseases.
YTD Price Performance: -10.26%
Average Trading Volume: 1,330,834
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.14B
See more insights into AUPH stock on TipRanks’ Stock Analysis page.
